Polymerized polynucleotides are currently the talk of the town when it comes to skin rejuvenation from within. Croma-Pharma proudly presents juvenus. Excellent PDRN fillers with anti-aging effect.
Croma-Pharma presents juvenus , a new injection gel based on polymerized polynucleotides for hydration of the skin and restoration of tissue elasticity
Croma-Pharma has expanded its product portfolio in the field of aesthetics with the medical product juvenus* . It is an absorbable injection gel based on polymerized polynucleotides (PDRN)[1],[2] of natural origin to hydrate the skin and restore tissue elasticity. juvenus is easy to inject, uniquely designed and specially developed to treat different skin needs on the face and body with quickly visible results.
Innovative approach to combat various signs of skin aging
juvenus, thanks to its special biochemical properties, increases the elasticity of the skin and effectively corrects various signs of natural and photoaging, such as wrinkles or loss of firmness and tone. Furthermore, fibrous tissue changes, such as scars, can be treated effectively.
High-molecular-weight polynucleotides (PDRN) have a positive effect on the skin in many ways:
- Antioxidant effect: enzyme-induced degradation of polynucleotide molecules may lead to enhanced protection against free radicals. [3]
- Hydration: Due to their hydrophilic and polyanionic properties, the polymerized polynucleotides contribute to the binding of water molecules, resulting in intense hydration of the tissue. Intradermal spaces are filled and the tissue becomes firmer.
- Fibroblast growth: The intense hydration as well as the antioxidant effect create an optimal physiological environment for stimulating the metabolic activity of fibroblasts. This favors the restoration of tissue elasticity. [4]
Two concentrations for different skin needs
juvenus is available in two concentrations and is suitable for all skin types and age groups:
- juvenus medium, PDRN 20 mg/ml: little pronounced wrinkles, such as superficial perioral wrinkles, wrinkles on the cheeks, medium scars.
- juvenus strong, PDRN 25 mg/ml: medium to deep wrinkles and larger body areas, such as neck, back of hands, abdomen, décolleté, thighs and buttocks, and deep/large scars.
Wide range of indications for facial and body treatments and good safety profile
The range of applications of juvenus is broadly defined and ranges from the treatment of facial wrinkles to the treatment of larger areas of the body.
juvenus has a good safety profile due to the extraction and purification of polynucleotides at high temperature. This process makes it possible to obtain a more than 95 percent pure active ingredient with inactivated proteins and peptides. This in turn guarantees the safety of the product and the absence of immunological side effects.
“Croma always strives to bring exceptional products to market that meet the growing demands of our customers. With juvenus, we can offer a new and safe injectable that specifically combats the signs of skin aging with an innovative approach to action,” comments Managing Director Andreas Prinz.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company specializing in the industrial production of hyaluronic acid syringes for medical aesthetics, ophthalmology and orthopedics. Croma currently operates 12 international sales companies and distributes its products in more than 70 countries. Within its worldwide distribution network, Croma focuses on minimally invasive aesthetic medicine with its own branded products. In addition to a wide range of HA fillers from its own production facility in Leobendorf, Croma sells PDO lifting threads, a platelet rich plasma system (PRP) and innovative skin care technologies in its strategic core markets.
For more information please visit
+41 52 633 0090
You would like to contact Croma-Pharma? Click here
[1] Müller Esterl, Biochemistry. 1st edition 2004, Elsevier
[2] Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L and Altavilla D (2017) Pharmacological Activity and Clinical Use of PDRN. Front. Pharmacol. 8:224. doi: 10.3389/fphar.2017.00224
[3] Cavallini M, Papagni M. Long chain polynucleotides gel and skin biorevitalization. Int J Plast Dermatol 2007; 3: 27-32.
[4] Pak CS, Lee J, Lee H, et al. A phase III, randomized, double-blind, matched-pairs, active-controlled clinical trial and preclinical animal study to compare the durability, efficacy and safety between polynucleotide filler and hyaluronic acid filler in the correction of crow’s feet: a new concept of regenerative filler. J Korean Med Sci 2014: 29: 201- 209.
